Xbrane Biopharma AB (publ), a biotechnology company, develops, manufactures, and sells biosimilars. The company is developing Ximluci, a ranibizumab biosimilar used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults. Its pre-clinical phase products include BIIB801, a biosimilar candidate for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease, and axial spondylitis; Xdivane for skin cancer, lung cancer, renal cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xtrudane for brain cancer, melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; and Xdarzane for multiple melanoma. Xbrane Biopharma AB (publ) was incorporated in 2008 and is headquartered in Solna, Sweden.
Stock data | 2024 | Change |
---|---|---|
Price | $0.016731155409707595 | N/A |
Market Cap | $498.76K | N/A |
Shares Outstanding | 29.81M | N/A |
Employees | 92.00 | N/A |